The KEYNOTE-811 trial demonstrated that pembrolizumab combined with trastuzumab and chemotherapy significantly improved PFS in HER-2 positive metastatic gastric/gastroesophageal junction adenocarcinoma patients with PD-L1 CPS ≥ 1. The gene discussed is ERBB2; the disease is gastroesophageal junction adenocarcinoma.